Heng Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heng Cui has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Yi Li
Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, China
20 shared publications - Xiaohong Chang
Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing 100044, China
17 shared publications - Danhua Shen
Department of Pathology, Peking University People’s Hospital, Beijing, China
15 shared publications - Honglan Zhu
Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing 100044, China
15 shared publications - Hongyan Cheng
School of Life Sciences, Biomedical Pioneering Innovation Center, Department of Obstetrics and Gynecology, People's Hospital, Peking University, Beijing, China
15 shared publications - Ruiqiong Ma
School of Life Sciences, Biomedical Pioneering Innovation Center, Department of Obstetrics and Gynecology, People's Hospital, Peking University, Beijing, China
15 shared publications
Latest Publications
- Open Access
- 26 December 2023
- Published by Elsevier in Neuroscience Applied
- Vol. 2, 102573
Cortical paired associative stimulation shows impaired plasticity of inhibition networks as a function of chronic alcohol use
- 26 December 2023
- Published by Elsevier in Neuroscience Applied
- Vol. 2, 102573
Open AccessCortical paired associative stimulation shows impaired plasticity of inhibition networks as a function of chronic alcohol use
- Open Access
- 27 November 2023
- Published by Wiley in Stem Cells International
- Vol. 2023, 1-15
Immunization with Embryonic Stem Cells/Induced Pluripotent Stem Cells Induces Effective Immunity against Ovarian Tumor-Initiating Cells in Mice
Cancer stem cells (CSCs) express pluripotent markers and share many features with normal pluripotent stem cells. It is possible that immunity induced by embryonic stem cells (ESCs) and induced pluripotent stem cells- (IPSCs-) based vaccines may selectively target CSCs. In our study, cells expressing the pluripotent marker CD133 in the murine ovarian cancer cell-line ID8 were isolated and identified as CSCs. We investigated the preventive efficacy of ESCs and IPSCs-based vaccines against the development of ovarian cancer in vivo and evaluated the humoral and cellular immunities targeting CSCs in vitro. Our study showed that preimmunization with both mouse-derived embryonic stem cells (mESCs) and mouse-induced pluripotent stem cells (mIPSCs) lysates, combined with an immunostimulatory adjuvant CpG, elicited strong humoral and cellular responses. These responses effectively suppressed the development of CSC-derived tumors. Immune sera collected from mESCs and mIPSCs-vaccinated mice contained antibodies that were capable of selectively targeting CSCs, resulting in the lysis of CSCs in the presence of complement. Cytotoxic T-lymphocytes generated from splenocytes of mESCs and mIPSCs-vaccinated hosts could secrete interferon- (IFN-) γ in response to CSCs and kill CSCs in vitro. These findings indicate that vaccines based on mESCs and mIPSCs can elicit effective antitumor immunities. These immunities are related to the conferring of humoral and cellular responses that directly target CSCs.
- 27 November 2023
- Published by Wiley in Stem Cells International
- Vol. 2023, 1-15
Open AccessImmunization with Embryonic Stem Cells/Induced Pluripotent Stem Cells Induces Effective Immunity against Ovarian Tumor-Initiating Cells in Mice
Cancer stem cells (CSCs) express pluripotent markers and share many features with normal pluripotent stem cells. It is possible that immunity induced by embryonic stem cells (ESCs) and induced pluripotent stem cells- (IPSCs-) based vaccines may selectively target CSCs. In our study, cells expressing the pluripotent marker CD133 in the murine ovarian cancer cell-line ID8 were isolated and identified as CSCs. We investigated the preventive efficacy of ESCs and IPSCs-based vaccines against the development of ovarian cancer in vivo and evaluated the humoral and cellular immunities targeting CSCs in vitro. Our study showed that preimmunization with both mouse-derived embryonic stem cells (mESCs) and mouse-induced pluripotent stem cells (mIPSCs) lysates, combined with an immunostimulatory adjuvant CpG, elicited strong humoral and cellular responses. These responses effectively suppressed the development of CSC-derived tumors. Immune sera collected from mESCs and mIPSCs-vaccinated mice contained antibodies that were capable of selectively targeting CSCs, resulting in the lysis of CSCs in the presence of complement. Cytotoxic T-lymphocytes generated from splenocytes of mESCs and mIPSCs-vaccinated hosts could secrete interferon- (IFN-) γ in response to CSCs and kill CSCs in vitro. These findings indicate that vaccines based on mESCs and mIPSCs can elicit effective antitumor immunities. These immunities are related to the conferring of humoral and cellular responses that directly target CSCs.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Figure from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Figure from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Data from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Table from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Figure from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
Supplementary Figure from Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer